Parametric Portfolio Associates LLC boosted its holdings in shares of ChemoCentryx Inc (NASDAQ:CCXI) by 4.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 41,105 shares of the biopharmaceutical company’s stock after acquiring an additional 1,808 shares during the period. Parametric Portfolio Associates LLC owned about 0.07% of ChemoCentryx worth $1,652,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also made changes to their positions in the company. Sowell Financial Services LLC acquired a new position in ChemoCentryx during the first quarter worth about $28,000. GQ Asset Management LLC acquired a new position in shares of ChemoCentryx in the first quarter valued at approximately $46,000. Exane Derivatives acquired a new position in shares of ChemoCentryx in the first quarter valued at approximately $86,000. Quantbot Technologies LP acquired a new position in shares of ChemoCentryx in the fourth quarter valued at approximately $98,000. Finally, Great West Life Assurance Co. Can acquired a new position in shares of ChemoCentryx in the fourth quarter valued at approximately $111,000. Institutional investors own 69.97% of the company’s stock.
A number of equities analysts have recently weighed in on the stock. Raymond James boosted their price objective on shares of ChemoCentryx from $38.00 to $102.00 and gave the company a “strong-buy” rating in a research report on Tuesday, May 12th. HC Wainwright restated a “buy” rating and issued a $69.00 target price on shares of ChemoCentryx in a report on Monday, May 18th. Wells Fargo & Co assumed coverage on shares of ChemoCentryx in a report on Wednesday, May 27th. They issued an “overweight” rating and a $79.00 target price for the company. Zacks Investment Research downgraded shares of ChemoCentryx from a “buy” rating to a “hold” rating in a report on Tuesday, May 12th. Finally, BTIG Research assumed coverage on shares of ChemoCentryx in a report on Tuesday, June 16th. They issued a “buy” rating and a $70.00 target price for the company. One analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $69.00.
ChemoCentryx (NASDAQ:CCXI) last released its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.05). ChemoCentryx had a negative return on equity of 100.55% and a negative net margin of 192.93%. The business had revenue of $6.01 million for the quarter, compared to analysts’ expectations of $8.90 million. Research analysts anticipate that ChemoCentryx Inc will post -1.39 earnings per share for the current year.
In other news, CEO Thomas J. Schall sold 90,753 shares of the company’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $65.08, for a total value of $5,906,205.24. Following the completion of the transaction, the chief executive officer now directly owns 2,357,310 shares in the company, valued at $153,413,734.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Thomas J. Schall sold 8,851 shares of the company’s stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $55.01, for a total transaction of $486,893.51. Following the completion of the transaction, the chief executive officer now owns 2,277,408 shares of the company’s stock, valued at $125,280,214.08. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 439,960 shares of company stock valued at $27,212,162. 9.30% of the stock is owned by insiders.
ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis; and Phase IIb clinical trial, the AURORA trial for the treatment of patients with moderate-to-severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy.
Featured Story: 52-Week High/Low Prices For Stock Selection
Want to see what other hedge funds are holding CCXI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ChemoCentryx Inc (NASDAQ:CCXI).
Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.